Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers

NCT02734992 | Completed

• 1 other identifier: K3_K1_0
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Research to date suggests that individuals with headache use avoidance as a way to manage their pain. Despite the wide use of avoidance as a coping mechanism of headache triggers, very little empirical evidence exist to support its effectiveness in headache management. New treatment approaches, such as Acceptance and Commitment Therapy (ACT), emphasize acceptance of headache and valued-living as alternatives to avoidance, have demonstrated preliminary support in helping individuals reduce headache-related disability and improve quality of life. Though, ACT has received empirical support for various chronic pain conditions, very little evidence exists as to its effectiveness for head pain problems. The current study will examine the efficacy of an ACT-based intervention, when added to medical treatment as usual (MTAU) vs. a waitlist control group across time (group differences at 3 months) and time changes for the ACT group at 12-months follow-up, on quality of life and general disability, among headache sufferers.

Conditions

Headache

Keywords

Migraines; Tension-type Headache; Acceptance

Outcome Measures

Primary Outcomes (2)

• The Henry Ford Hospital Headache Disability Inventory (b-HDI; Jacobson, Ramadan, Aggarwal & Newman, 1994)

  b-HDI is a 25-item headache disability inventory assesses the effect of headaches on daily activities (e.g. 'Because of my headaches I am less likely to socialize') and emotional functioning (e.g. 'I feel desperate because of my headaches'). Items are divided into two sub-grouped scales: functional, representing the sensory component of headaches (e.g. intensity etc) (13-items); and emotional (12-items), representing the reactive or affective realm (Andrasik, Lipchik, McCrory, \& Wittrock, 2005). The instrument is answered with "yes", "no" or "sometimes" and the higher the score the greater the disability caused by the headache. The b-HDI has shown high reliability (a=.84) and validity with other similar scales. For the purpose of this study, only the general headache disability score will be used, comprising of the two subscales.

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

• The Migraine- Specific Quality of Life Questionnaire (MSQ v 2.1; Martin et al., 2000; under permission given by GlaxoSmithKline; GSK USMA health outcome group),

  The MSQ is a 14-items migraine-specific Likert-type scale assesses the impact of migraines on patients' quality of life over the past four weeks. The scale is divided into three dimensions: Role Restrictive (RR; 7 items), Role Preventive (RP; 4 items), and Emotional Function (EF; 3 items). Role- function restrictive describes the degree to which performance of daily activities are limited by migraines. Role Preventive (RP) assesses the amount of normal activities interrupted by migraines. The Emotional Function (EF) evaluates the degree of emotional effects of migraine (e.g., frustration, afraid and burden). Items ranged from 1 (none of the time) to 6 (all of the time). The revised MSQ (version 2.1) appears with sufficient psychometric validity and reliability (a coefficient= .86- .96), across different migraine groups (Cole, Lin \& Rupnow, 2007; Rendas- Baum, Bloudek, Maglinte \& Varon, 2013). For the purpose of this study the three dimensions will be used to assess functional changes.

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

Secondary Outcomes (4)

• The Hospital Anxiety and Depression Scale (HADS; Zigmond, & Snaith, 1983)

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

• Greek Brief pain inventory: the pain severity subscale (G-BPI; Mystakidou, Mendoza,

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

• Number of visits to different physicians due to Headache (Adapted with permission from Vowles et al., 2008)

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

• Number of medical utilization (# visits to primary care for HA, #visits to Emergency, #department for HA, # hospitalization due to HAs (adapted with permission from Vowles et al., 2008).

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

Other Outcomes (5)

• The Chronic Pain Acceptance Questionnaire (G-CPAQ Greek adaptation; Vasiliou et al., 2017; Original McCracken et al, 2004)

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

• Psychological inflexibility in pain scale (G-PIPS; Greek adaptation; Vasiliou et al., 2019; PIPS-II; Wicksell, Lekander, Sorjonen & Olsson, 2010)

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

• Committed Action Questionnaire (CAQ; McCracken, Chilcot, & Norton, 2014),

  Group by time Changes from Baseline Headache Disability at 3 months follow-up

Study Arms (2)

Acceptance and Commitment therapy + MTAU

OTHER

The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou \& Karekla, 2015). The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness. Participants will be asked to remain stable on their pharmacotherapy during this study. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Participants will complete questionnaires at pre-, post-treatment, and at 3-month follow-up. The WL group will enter treatment at the 3-month follow-up of the ACT-group.

Behavioral: ACT+ MTAU

MTAU/ Wait-list Control Gr

OTHER

The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment. Participants will complete the same questionnaires at three different time points: pre-, post-treatment, and at 3-month follow-up. Participants will be asked to remain stable on their pharmacotherapy during this study and inform the researchers of any changes. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Excluded participants will be referred to appropriate services.

Behavioral: Waitlist Control +MTAU

Interventions

ACT+ MTAU BEHAVIORAL

Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.

Also known as: The ALGEA STUDY

Acceptance and Commitment therapy + MTAU

Waitlist Control +MTAU BEHAVIORAL

Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.

MTAU/ Wait-list Control Gr

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• meeting diagnostic criteria for Primary Headache based on the International Classification of Headache Disorders-II (beta version; 2013);
• older than 18 years; c) sufficient Greek reading ability; and d) stable pharmacotherapy and headache experience (both remained unchanged for the past four weeks prior to assessment).

You may not qualify if:

• had an active psychotic spectrum condition or manic episode, suicidal ideation/intent or substance use problems (particularly misuse of prescription head pain relievers) within the past 6 months;
• had a history of seizure, facial neuralgia or other secondary headache diagnoses (i.e., conditions that might preclude the accuracy of primary headache diagnosis);
• scored \<20 on the Mini-mental Status Examination suggesting significant cognitive impairment;
• were living in nursing homes;
• had multiple pain sides (pain experienced in multiple body sides or groups of muscles);
• took part in other psychological interventions or counseling (particularly for managing headache) over the last two years;
• were pregnant or lactating.

Sponsors & Collaborators

• University of Cyprus: lead
• University of Crete: collaborator

Study Sites (1)

University of Cyprus

Nicosia, 20537, Cyprus

Location

Related Publications (1)

• Vasiliou VS, Karademas EC, Christou Y, Papacostas S, Karekla M. Mechanisms of change in acceptance and commitment therapy for primary headaches. Eur J Pain. 2022 Jan;26(1):167-180. doi: 10.1002/ejp.1851. Epub 2021 Aug 18.

  PMID: 34375444 DERIVED

MeSH Terms

Conditions

Headache; Migraine Disorders; Tension-Type Headache

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Licensed Clinical Psychologist, Assistant Professor, Peer reviewed ACT trainer,

Study Record Dates

• First Submitted: March 21, 2016
• First Posted: April 12, 2016
• Study Start: September 1, 2014
• Primary Completion: March 1, 2015
• Study Completion: December 1, 2016
• Last Updated: July 16, 2019

Record last verified: 2019-07

Data Sharing

• IPD Sharing: Will not share

Locations

CY (1)